2026 Cure CMD International Research Grants in Congenital Muscular Dystrophy
The 2026 Cure CMD International Research Grants support global scientific research on L-CMD and αDG subtypes of congenital muscular dystrophy to advance understanding and accelerate therapy development.
Funder: Cure CMD
Due Dates: July 27, 2026 (Letter of Intent) | September 14, 2026 (Full Proposal, by invitation)
Funding Amounts: Up to $100,000 over 2 years (L-CMD) | Up to $50,000 over 2 years (αDG); max 10% indirect costs allowed
Summary: Supports international research on congenital muscular dystrophy, focusing on L-CMD and αDG subtypes, to advance disease understanding and therapeutic development.
Key Information: LOI required; only selected applicants may submit full proposals.
Description
Cure CMD’s 2026 international research grants are designed to accelerate discovery and therapeutic development for two critical subtypes of congenital muscular dystrophy: Congenital Onset Laminopathies (L-CMD) and Congenital Onset Dystroglycanopathies (αDG). The initiative seeks innovative research that deepens understanding of disease mechanisms, identifies and validates new therapeutic targets, and advances promising treatments toward clinical trial readiness. For L-CMD, emphasis is placed on addressing cardiac complications alongside skeletal muscle weakness. For αDG, research exploring both muscular and neurological manifestations—including cognitive and neural impacts—is strongly encouraged. Eligible projects may include disease modeling, biomarker discovery, outcome measure development, and preclinical or translational research with the potential to improve care for individuals worldwide.
